Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT Chronic Malignancies and Lymphoma Working Parties

被引：54

作者：

Dreger, Peter ^{[1
,2
,3
]}

Michallet, Mauricette ^{[4
]}

Bosman, Paul ^{[1
]}

Dietrich, Sascha ^{[2
,3
]}

Sobh, Mohamad ^{[4
]}

Boumendil, Ariane ^{[2
]}

Nagler, Arnon ^{[5
]}

Scheid, Christof ^{[6
]}

Cornelissen, Jan ^{[7
]}

Niederwieser, Dietger ^{[8
]}

Mueller, Lutz ^{[9
]}

Vandenberghe, Elizabeth ^{[10
]}

Scortechini, Ilaria ^{[11
]}

Schoemans, Helene ^{[12
,13
]}

Andersen, Niels S. ^{[14
]}

Finke, Juergen ^{[15
]}

Russo, Domenico ^{[16
]}

Ljungman, Per ^{[17
]}

Passweg, Jakob ^{[18
]}

van Gelder, Michel ^{[1
,19
]}

Durakovic, Nadira ^{[20
]}

Labussiere-Wallet, Helene ^{[21
]}

Berg, Tobias ^{[22
]}

Wulf, Gerald ^{[23
]}

Bethge, Wolfgang ^{[24
]}

Bunjes, Donald ^{[25
]}

Stilgenbauer, Stefan ^{[25
]}

Canepari, Maria Elisa ^{[26
]}

Schaap, Michel ^{[27
]}

Fox, Christopher P. ^{[28
]}

Kroeger, Nicolaus ^{[1
,29
]}

Montoto, Silvia ^{[2
,30
]}

Schetelig, Johannes ^{[1
,31
]}

机构：

[1] EBMT Chron Malignancies Working Party, Leiden, Netherlands

[2] EBMT Lymphoma Working Party, Paris, France

[3] Heidelberg Univ, Dept Med 5, Heidelberg, Germany

[4] Ctr Leon Berard, Serv Hematol, Lyon, France

[5] Chaim Sheba Med Ctr, Hematol Div, Ramat Gan, Israel

[6] Univ Cologne, Cologne, Germany

[7] Erasmus MC Canc Ctr, Dept Hematol, Rotterdam, Netherlands

[8] Univ Hosp, Dept Hematol & Med Oncol, Leipzig, Germany

[9] Martin Luther Univ Halle Wittenberg, Halle, Germany

[10] St James Hosp, Hope Directorate, Dublin, Ireland

[11] Osped Riuniti Ancona, Dept Haematol, Ancona, Italy

[12] Univ Hosp Leuven, Dept Hematol, Leuven, Belgium

[13] Katholieke Univ Leuven, Leuven, Belgium

[14] Rigshosp, Copenhagen, Denmark

[15] Univ Freiburg, Dept Med 1, Freiburg, Germany

[16] Univ Brescia, Chair Hematol, ASST Spedali Civili, Unit Blood Dis & Bone Marrow Transplantat, Brescia, Italy

[17] Karolinska Univ Hosp, Dept Cellular Therapy & Allogene Stem Cell Transp, Stockholm, Sweden

[18] Univ Hosp, Basel, Switzerland

[19] Maastricht Univ, Med Ctr, Dept Internal Med, Hematol Div, Maastricht, Netherlands

[20] Univ Hosp Ctr Rebro, Zagreb, Croatia

[21] Ctr Hosp Lyon Sud, Lyon, France

[22] Goethe Univ, Dept Med 2, Frankfurt, Germany

[23] Univ Klinikum Gottingen, Gottingen, Germany

[24] Univ Hosp Tuebingen, Med Ctr, Dept Hematol & Oncol, Tubingen, Germany

[25] Univ Hosp Ulm, Dept Med 3, Ulm, Germany

[26] Az Osped S Croce & Carle, Cuneo, Italy

[27] Radboud Univ Nijmegen, Dept Hematol, Med Ctr Nijmegen, Nijmegen, Netherlands

[28] Nottingham Univ Hosp NHS Trust, Clin Haematol, Nottingham, England

[29] Univ Hosp Eppendorf, Hamburg, Germany

[30] Barts Hlth NHS Trust, St Bartholomews Hosp, Dept Haematooncol, London, England

[31] Univ Klinikum Dresden, Dresden, Germany

来源：

BONE MARROW TRANSPLANTATION | 2019年 / 54卷 / 01期

关键词：

TERM-FOLLOW-UP; HIGH-RISK CLL; EUROPEAN-SOCIETY; DISEASE-CONTROL; THERAPY; FAILURE; SURVIVAL; OUTCOMES; BLOOD; ERA;

D O I：

10.1038/s41409-018-0207-4

中图分类号：

Q6 [生物物理学];

学科分类号：

071011 ;

摘要：

The aim of this retrospective study was to investigate the safety and efficacy of allogeneic hematopoietic cell transplantation (alloHCT) in patients pre-treated with ibrutinib. Eligible were patients aged >18 years allotransplanted for chronic lymphocytic leukemia (CLL) or mantle cell lymphoma (MCL) after prior exposure to ibrutinib who were registered with the EBMT registry. Seventy patients (CLL 48, MCL 22) were included. At the time of alloHCT, 73% of the patients were ibrutinib responsive. All patients except one engrafted, and acute GVHD grade 2-4 (3-4) was observed in 49% (12%) of 68 evaluable patients. The cumulative incidence of chronic GVHD was 54% 1 year after transplant. In the CLL group, 12-month non-relapse mortality, relapse incidence (RI), progression-free survival (PFS), and overall survival (OS) were 10, 30, 60, and 72%, respectively, and in the MCL group 5, 19, 76, and 86%, respectively. Pre-transplant ibrutinib failure and poor performance status predicted inferior RI, PFS and OS in the CLL group. In conclusion, ibrutinib does not affect the safety of a subsequent alloHCT. While the relatively high post-transplant relapse risk in ibrutinib-exposed patients with CLL deserves further study, in patients with MCL consolidating disease responses to ibrutinib with alloHCT seems to be a promising option.

引用

页码：44 / 52

页数：9

共 34 条

[1] Defining the Intensity of Conditioning Regimens: Working Definitions [J].

Bacigalupo, Andrea ;

Ballen, Karen ;

Rizzo, Doug ;

Giralt, Sergio ;

Lazarus, Hillard ;

Ho, Vincent ;

Apperley, Jane ;

Slavin, Shimon ;

Pasquini, Marcelo ;

Sandmaier, Brenda M. ;

Barrett, John ;

Blaise, Didier ;

Lowski, Robert ;

Horowitz, Mary .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2009, 15 (12) :1628-1633

[2] Long-term follow-up of reduced-intensity allogeneic stem cell transplantation for chronic lymphocytic leukemia: prognostic model to predict outcome [J].

Brown, J. R. ;

Kim, H. T. ;

Armand, P. ;

Cutler, C. ;

Fisher, D. C. ;

Ho, V. ;

Koreth, J. ;

Ritz, J. ;

Wu, C. ;

Antin, J. H. ;

Soiffer, R. J. ;

Gribben, J. G. ;

Alyea, E. P. .

LEUKEMIA, 2013, 27 (02) :362-369

[3] Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia [J].

Byrd, J. C. ;

Brown, J. R. ;

O'Brien, S. ;

Barrientos, J. C. ;

Kay, N. E. ;

Reddy, N. M. ;

Coutre, S. ;

Tam, C. S. ;

Mulligan, S. P. ;

Jaeger, U. ;

Devereux, S. ;

Barr, P. M. ;

Furman, R. R. ;

Kipps, T. J. ;

Cymbalista, F. ;

Pocock, C. ;

Thornton, P. ;

Caligaris-Cappio, F. ;

Robak, T. ;

Delgado, J. ;

Schuster, S. J. ;

Montillo, M. ;

Schuh, A. ;

de Vos, S. ;

Gill, D. ;

Bloor, A. ;

Dearden, C. ;

Moreno, C. ;

Jones, J. J. ;

Chu, A. D. ;

Fardis, M. ;

McGreivy, J. ;

Clow, F. ;

James, D. F. ;

Hillmen, P. .

NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (03) :213-223

[4] Entering the Era of Targeted Therapy for Chronic Lymphocytic Leukemia: Impact on the Practicing Clinician [J].

Byrd, John C. ;

Jones, Jeffrey J. ;

Woyach, Jennifer A. ;

Johnson, Amy J. ;

Flynn, Joseph M. .

JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (27) :3039-3047

[5] Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes [J].

Cheah, C. Y. ;

Chihara, D. ;

Romaguera, J. E. ;

Fowler, N. H. ;

Seymour, J. F. ;

Hagemeister, F. B. ;

Champlin, R. E. ;

Wang, M. L. .

ANNALS OF ONCOLOGY, 2015, 26 (06) :1175-1179

[6] How should we sequence and combine novel therapies in CLL? [J].

Davids, Matthew S. .

HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2017, :346-353

[7] Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning [J].

Dreger, P ;

Brand, R ;

Hansz, J ;

Milligan, D ;

Corradini, P ;

Finke, J ;

Deliliers, GL ;

Martino, R ;

Russell, N ;

van Biezen, A ;

Michallet, M ;

Niederwieser, D .

LEUKEMIA, 2003, 17 (05) :841-848

[8] Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents? [J].

Dreger, Peter ;

Schetelig, Johannes ;

Andersen, Niels ;

Corradini, Paolo ;

van Gelder, Michel ;

Gribben, John ;

Kimby, Eva ;

Michallet, Mauricette ;

Moreno, Carol ;

Stilgenbauer, Stephan ;

Montserrat, Emili .

BLOOD, 2014, 124 (26) :3841-3849

[9] Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial [J].

Dreger, Peter ;

Doehner, Hartmut ;

Ritgen, Matthias ;

Boettcher, Sebastian ;

Busch, Raymonde ;

Dietrich, Sascha ;

Bunjes, Donald ;

Cohen, Sandra ;

Schubert, Joerg ;

Hegenbart, Ute ;

Beelen, Dietrich ;

Zeis, Matthias ;

Stadler, Michael ;

Hasenkamp, Justin ;

Uharek, Lutz ;

Scheid, Christof ;

Humpe, Andreas ;

Zenz, Thorsten ;

Winkler, Dirk ;

Hallek, Michael ;

Kneba, Michael ;

Schmitz, Norbert ;

Stilgenbauer, Stephan .

BLOOD, 2010, 116 (14) :2438-2447

[10] Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase study [J].

Dreyling, Martin ;

Jurczak, Wojciech ;

Jerkeman, Mats ;

Silva, Rodrigo Santucci ;

Rusconi, Chiara ;

Trneny, Marek ;

Offner, Fritz ;

Caballero, Dolores ;

Joao, Cristina ;

Witzens-Harig, Mathias ;

Hess, Georg ;

Bence-Bruckler, Isabelle ;

Cho, Seok-Goo ;

Bothos, John ;

Goldberg, Jenna D. ;

Enny, Christopher ;

Traina, Shana ;

Balasubramanian, Sriram ;

Bandyopadhyay, Nibedita ;

Sun, Steven ;

Vermeulen, Jessica ;

Rizo, Aleksandra ;

Rule, Simon .

LANCET, 2016, 387 (10020) :770-778

← 1 2 3 4 →